←
Michael Cilento54 posts
Michael Cilento avatar✓

Michael Cilento ✓

@drcilento

Medical Oncologist & PhD candidate. Passionate about precision oncology and #ProstateCancer research 🧬 @SAiGENCI / @uniofadelaide

◷ Joined March 2020▧ 4 Photos and videos
Anis Hamid avatar
⟳ Michael Cilento retweeted
Anis Hamid@anis_a_hamid·May 30

Decipher is consistent across trials in IDing group benefiting from intensification. @ChrisSweens1 presents data from ENZAMET - great collab btw @Decipher_VCYT @ANZUPtrials and participating centers. More molecular data coming from ENZAMET - see our germline profiling poster tmrw

Post attachment
Advanced Prostate Cancer Consensus Conference avatar
⟳ Michael Cilento retweeted
Advanced Prostate Cancer Consensus Conference@APCCC_Lugano·1 Dec 2025

Personalized intensification of treatment for hormone-sensitive prostate cancer nature.com/articles/s41571-0… Hormone-sensitive #ProstateCancer (HSPC) management has advanced beyond androgen-deprivation therapy (ADT) alone, now incorporating androgen receptor pathway inhibitors (ARPIs), docetaxel, and radiotherapy based on disease state and biology. Modern PSMA PET imaging detects metastases earlier than conventional scans, redefining patient subgroups and influencing decisions such as when to use chemotherapy or radiotherapy. Treatment is increasingly personalized, guided by prior local therapy, PSA dynamics, disease volume, and imaging findings, with ARPI–ADT doublets forming the backbone for metastatic disease. Attention to toxicity from long-term testosterone suppression is crucial, while emerging biomarker-driven therapies—including ^177Lu-PSMA-617, AKT inhibitors, and PARP inhibitors—are poised to further refine care. @drcilento @LisaButler5 @drlouiseemmett @ChrisSweens1 @OncoAlert 🚨 @Silke_Gillessen @AOmlin @weoncologists

Post attachment
Michael Hofman avatar
⟳ Michael Cilento retweeted
Michael Hofman@DrMHofman·27 May 2025

Stunning research from @EdmondMKwan on ctDNA in theranostics: 🧬Low ctDNA predicts better response with ¹⁷⁷Lu-PSMA-617 vs. cabazitaxel chemotherapy ⚠️PTEN alterations linked to worse outcomes on cabazitaxel 🧪ATM defects tied to favorable PSMA-617 results 🩻PET quantitative biomarkers (SUVmean) are additive 🌟We identify new candidate biomarkers for ¹⁷⁷Lu–PSMA-617 selection and ultimately expand the mCRPC predictive biomarker repertoire Online at @NatureMedicine nature.com/articles/s41591-0… @ANZUPtrials #TheraP @MovemberAUS @PCFA Support by @PCF_Science Challenge Award @ResearchWyatt @AzadOncology @Prof_IanD

Post attachmentPost attachmentPost attachmentPost attachment